Abstract
Purpose of ReviewGiven the recent increase in the profile and use of Janus kinase inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the current evidence accruing for use in paediatric rheumatology patients.Recent FindingsSignificant advances have been made in the management of rheumatic diseases in the past two decades. The introduction of biologic agents in both adults and children has provided significant improvements to patient outcomes and led to better quality of life. Moreover, responses to similar agents allude to common effector pathways operating across juvenile and adult synovitis especially. However, inefficacy and intolerance of these agents leads to a subset of children with limited treatment options.SummarySince 2012, Janus kinase (JAK) inhibitors (JAKinibs), a novel group of oral small molecule inhibitors, have demonstrated their efficacy in several forms of adult inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). There are hopes that these successes will be transferable to the paediatric population. In the following review, we discuss the development and progress of JAKinibs in this regard.
Highlights
The treatment of paediatric rheumatic diseases has evolved markedly over the past two decades
Janus kinase (JAK)-mediated pathways are known to be implicated in the pathogenesis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), Topical Collection on Pediatric Rheumatology
We discuss below the current knowledge base and progress in establishing the role for JAKinibs within paediatric rheumatology
Summary
The treatment of paediatric rheumatic diseases has evolved markedly over the past two decades. The development of biological disease-modifying anti-rheumatic drugs (bDMARDs) has provided a significant armamentarium to rheumatologists, improving clinical outcomes for patients. JAK-mediated pathways are known to be implicated in the pathogenesis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), inflammatory bowel disease (IBD), Topical Collection on Pediatric Rheumatology. BDMARDs targeting cytokines implicated in pro-inflammatory pathways, such as interleukin-1 and -6 (IL-1 and IL-6), and tumour necrosis factor-α (TNF-α), amongst others, have markedly advanced the treatment of otherwise recalcitrant disease. JAKinibs have been approved for use in adults with RA and PsA, and phase 3 studies are underway to establish the role and efficacy of these molecules in the treatment of JIA. We discuss below the current knowledge base and progress in establishing the role for JAKinibs within paediatric rheumatology
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
